Alerts
Pancreatic Cancer’s ADC Moment Will Live or Die by the Biomarker
Early ESMO GI data suggest that a CEACAM5-targeted antibody–drug conjugate may have activity in selected patients with refractory pancreatic cancer. The opportunity is real. So is the danger of treating biomarker selection as a box-ticking exercise.
Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test
Ebola PHEIC Turns Outbreak Control Into a Preparedness Test
Huntington’s Disease Gets an Oral Target-Engagement Signal
A New CELMoD Raises the Bar in Relapsed Myeloma
IPM Alliance launches at the World Health Assembly in Geneva
Regulators Start Writing the Rules for AI-Driven Medicines
FDA Puts AI Inside the Evidence Machine
AI Diagnosis Has Entered the Access Debate
Lenacapavir Turns HIV Prevention Into an Access Stress Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.